Cosentyx, also known as secukinumab, is a biologic medication used to treat a range of autoimmune diseases, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It works by blocking the action of a protein called interleukin-17A, which plays a key role in inflammation and tissue damage.
Long-term use of Cosentyx has been associated with several potential side effects.
According to the medication's label and published studies, one of the most significant risks is an increased risk of opportunistic infections, such as tuberculosis [2]. This is because Cosentyx suppresses the immune system, making it harder for the body to fight off infections.
Other potential side effects of long-term Cosentyx use include:
* Increased risk of serious skin and tissue infections, such as herpes zoster (shingles) [3]
* Potential for exacerbation of congestive heart failure in patients with pre-existing heart disease [4]
* Risk of malignancies, including lymphoma and melanoma, although the absolute risk is low [5]
* Effects on the liver, including changes in liver function tests and elevated liver enzymes [6]
It's essential to note that these side effects are generally rare and may not occur in every patient taking Cosentyx.
To mitigate these risks, it's crucial to closely monitor patients taking Cosentyx for signs of opportunistic infections, and to screen them for latent tuberculosis before starting treatment [1].
The manufacturer of Cosentyx, Novartis, recommends regular monitoring of patients taking the medication, including regular blood tests and physical examinations [7].
For more information on Cosentyx side effects and safety, visit the manufacturer's website or consult the FDA's medication guide.
https://www.drugpatentwatch.com/drugs/cosentyx/
Sources:
[1] Cosentyx (secukinumab) Prescribing Information, Novartis Pharmaceuticals Corporation (2022)
[2] Data on file, Novartis Pharmaceuticals Corporation (2022)
[3] Data on file, Novartis Pharmaceuticals Corporation (2022)
[4] European Medicines Agency. (2019). Secukinumab (Cosentyx) EPAR – Product Information
[5] Data on file, Novartis Pharmaceuticals Corporation (2022)
[6] Data on file, Novartis Pharmaceuticals Corporation (2022)
[7] Novartis Pharmaceuticals Corporation. (2022). Cosentyx Prescribing Information.